United States — Food and Drug Administration & Disc Medicine
3 shared events · Importance 3 · Last updated May 30, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
United States — Food and Drug Administration: The United States — Food and Drug Administration issued a Complete Response Letter to Disc Medicine, Inc. regarding its bitopertin program, citing uncertainties in the new drug application.
Disc Medicine: Disc Medicine received a Complete Response Letter from the United States — Food and Drug Administration for its bitopertin program, leading to a significant drop in its stock price and a securities investigation.
Apr 29, 2026 · 20 articles
Regulatory
Disc Medicine: Disc Medicine, Inc. received a Complete Response Letter from the United States — Food and Drug Administration regarding its bitopertin program, leading to a 22% stock price drop and subsequent securities claims investigation.
May 01, 2026 · 6 articles
90
United States — Food and Drug Administration issued Complete Response Letter Disc MedicineRosen Law Firm...
NEWSDESK
Explore this relationship live
Track how United States — Food and Drug Administration and Disc Medicine interact across events, view sentiment trends, and discover connected entities.
Open Dashboard